{"id":477070,"date":"2021-04-15T09:33:10","date_gmt":"2021-04-15T13:33:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-chairman-ceo-lishan-aklog-m-d-named-top-50-healthcare-technology-ceo-by-healthcare-technology-report\/"},"modified":"2021-04-15T09:33:10","modified_gmt":"2021-04-15T13:33:10","slug":"pavmed-chairman-ceo-lishan-aklog-m-d-named-top-50-healthcare-technology-ceo-by-healthcare-technology-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-chairman-ceo-lishan-aklog-m-d-named-top-50-healthcare-technology-ceo-by-healthcare-technology-report\/","title":{"rendered":"PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report"},"content":{"rendered":"
\n

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ<\/strong>) (the \u201cCompany\u201d or \u201cPAVmed\u201d), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer and Executive Chairman of its majority-owned subsidiary, Lucid Diagnostics Inc., was selected as one of the Top 50 Healthcare Technology CEOs of 2021 by Healthcare Technology Report<\/a>.<\/p>\n

\u201cI am humbled to be named among such a prominent and accomplished group of industry leaders,\u201d said Dr. Aklog. \u201cThis honor is first and foremost a recognition of PAVmed\u2019s incredible team, who are working tirelessly, along with our world-class partners and advisors, to advance and commercialize groundbreaking innovations to improve patient care and save lives.\u201d<\/p>\n

Healthcare Technology Report described this year\u2019s awardees as representing \u201csome of the most accomplished executives in healthcare technology\u201d whose \u201cleadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies\u201d and who have made \u201csignificant contributions to society at large.\u201d Its editors evaluated hundreds of CEOs in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. Nominees were assessed across several key areas including breadth of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team\u2019s experience and consistency of organizational performance. Notably, in addition to overseeing their companies\u2019 efforts from the C-suite, many of these leaders were also, as Dr. Aklog is, founders or co-founders of their organizations, recognizing unique opportunities for transformation and growth within their areas of expertise. Dr. Aklog joins the list alongside CEOs of leading medical device and diagnostic technology companies including Medtronic, Thermo Fisher, BD, Edwards Lifesciences, DexCom, Ortho Clinical Diagnostic and Guardant Health.<\/p>\n

\n About Lishan Aklog, M.D.<\/strong>\n <\/p>\n

Dr. Lishan Aklog serves as Chairman & CEO of PAVmed, Inc. (Nasdaq: PAVM, PAVMZ) which he and his partners co-founded with a vision to build a high-growth multi-product medical technology company advancing and commercializing a portfolio of groundbreaking products, starting with their own innovations and expanded through acquisition or licensing of technologies from academic medical centers or clinician innovators. Dr. Aklog serves concurrently as Executive Chairman of PAVmed\u2019s major subsidiary, Lucid Diagnostics Inc., which markets the only commercially available tools for early precancer detection to prevent esophageal cancer in patients with chronic heartburn. He also serves on the board of directors of two life sciences companies, and the leading medical technology trade association, AdvaMed. He and his partners previously co-founded Pavilion Holdings Group, which created four medical device companies, including Vortex Medical, which developed and commercialized his life-saving invention AngioVac\u00ae<\/sup> prior to its acquisition by Angiodynamics (Nasdaq: ANGO). Before he transitioned to a career as an entrepreneur and executive in the life sciences industry, Dr. Aklog had a distinguished academic and clinical career as a technological innovator in cardiac surgery, serving on the faculty of leading institutions, including Harvard Medical School and Mount Sinai School of Medicine. He received his A.B. degree from Harvard College, graduating Phi Beta Kappa and magna cum laude<\/em> in Physics and his M.D. degree, cum laude<\/em>, from Harvard Medical School. He completed his surgical training at Harvard\u2019s Brigham and Women\u2019s Hospital and Boston Children\u2019s Hospital, Harefield Hospital, London and L\u2019Ho\u0302pital Broussais, Paris. Dr. Aklog, who fled political violence in Ethiopia as a young teenager, has been active in philanthropic organizations, including as a member of the international board of directors of Human Rights Watch.<\/p>\n

\n About PAVmed<\/strong>\n <\/p>\n

PAVmed Inc. is a multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed\u2019s diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard\u00ae<\/sup> Esophageal DNA Test, EsoCheck\u00ae<\/sup> Esophageal Cell Collection Device, and EsoCure\u2122<\/sup> Esophageal Ablation Device with Caldus\u2122<\/sup> Technology), Minimally Invasive Interventions (CarpX\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO\u2122<\/sup> Implantable Intraosseus Vascular Access Device and NextFlo\u2122<\/sup> Highly Accurate Infusion Platform Technology), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit\u00a0www.pavmed.com<\/a>, follow us on Twitter<\/a>, connect with us on LinkedIn<\/a>, and watch our videos on YouTube<\/a>. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com<\/a>, follow Lucid on Twitter<\/a>, and connect with Lucid on LinkedIn<\/a>. For detailed information on EsoGuard, please visit www.EsoGuard.com<\/a> and follow us on Twitter<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed\u2019s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed\u2019s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed\u2019s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed\u2019s preclinical studies; whether and when PAVmed\u2019s products are cleared by regulatory authorities; market acceptance of PAVmed\u2019s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company\u2019s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed\u2019s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed\u2019s future operations, see Part I, Item IA, \u201cRisk Factors,\u201d in PAVmed\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \u201cRisk Factors\u201d in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/u>
\n
Mike Havrilla
Director of Investor Relations
(814) 241-4138
JMH@PAVmed.com<\/a><\/p>\n

\n Media<\/u>
\n
Shaun O\u2019Neil
Chief Commercial Officer
(518) 812-3087
SMO@PAVmed.com<\/a><\/p>\n

Katie Gallagher
LaVoieHealthScience
(617) 792-3937
PAVmed@lavoiehealthscience.com<\/a><\/p>\n

###<\/p>\n<\/p>\n

\n Attachment<\/strong>\n <\/p>\n